AU6724598A - 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors - Google Patents

5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors

Info

Publication number
AU6724598A
AU6724598A AU67245/98A AU6724598A AU6724598A AU 6724598 A AU6724598 A AU 6724598A AU 67245/98 A AU67245/98 A AU 67245/98A AU 6724598 A AU6724598 A AU 6724598A AU 6724598 A AU6724598 A AU 6724598A
Authority
AU
Australia
Prior art keywords
proteinsinhibitors
chinolines
oxysubstituted
cholesterol ester
ester transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67245/98A
Inventor
Rolf Angerbauer
Hilmar Bischoff
Arndt Brandes
Klaus-Dieter Bremm
Michael Logers
Matthias Muller-Gliemann
Carsten Schmeck
Delf Schmidt
Gunter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU6724598A publication Critical patent/AU6724598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU67245/98A 1997-03-06 1998-02-24 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors Abandoned AU6724598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19709125A DE19709125A1 (en) 1997-03-06 1997-03-06 Substituted quinolines
DE19709125 1997-03-06
PCT/EP1998/001046 WO1998039299A1 (en) 1997-03-06 1998-02-24 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteins inhibitors

Publications (1)

Publication Number Publication Date
AU6724598A true AU6724598A (en) 1998-09-22

Family

ID=7822418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67245/98A Abandoned AU6724598A (en) 1997-03-06 1998-02-24 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors

Country Status (5)

Country Link
EP (1) EP0970053A1 (en)
JP (1) JP2001513790A (en)
AU (1) AU6724598A (en)
DE (1) DE19709125A1 (en)
WO (1) WO1998039299A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19741051A1 (en) * 1997-09-18 1999-03-25 Bayer Ag New tetrahydroquinoline derivatives useful in treatment of raised lipid levels and arteriosclerosis
DE19741399A1 (en) * 1997-09-19 1999-03-25 Bayer Ag New tetrahydroquinoline derivatives useful in treatment of elevated lipid levels and arteriosclerosis
PT1115693E (en) * 1998-09-25 2007-08-02 Monsanto Co Substituted polycyclic aryl and heteroaryl $i(tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6544974B2 (en) 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
FR2820435B1 (en) * 2001-02-05 2004-02-27 Genfit S A METHODS OF IDENTIFYING COMPOUNDS MODULATING THE REVERSE TRANSPORT OF CHOLESTEROL
KR100759635B1 (en) 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 Pharmaceutical compositions of adsorbates of amorphous drug
DE60233874D1 (en) 2001-06-22 2009-11-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS CONTAIN DISPERSIONS FROM MEDICAMENTS AND NEUTRAL POLYMERS
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AR038375A1 (en) 2002-02-01 2005-01-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
MXPA05009976A (en) 2003-03-17 2005-11-04 Japan Tobacco Inc Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate.
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
CA2554982A1 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
ATE442358T1 (en) 2003-10-08 2009-09-15 Lilly Co Eli COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
KR20070001922A (en) 2003-12-12 2007-01-04 와이어쓰 Quinolines useful in treating cardiovascular disease
WO2005097806A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
KR20070090248A (en) 2004-12-18 2007-09-05 바이엘 헬스케어 아게 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2009512715A (en) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent
DE102006012548A1 (en) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituted chromanol derivatives and their use
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
DE19610932A1 (en) * 1996-03-20 1997-09-25 Bayer Ag 2-aryl substituted pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines

Also Published As

Publication number Publication date
JP2001513790A (en) 2001-09-04
DE19709125A1 (en) 1998-09-10
EP0970053A1 (en) 2000-01-12
WO1998039299A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
AU6724598A (en) 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteinsinhibitors
EP0926468B8 (en) Display
AU2451097A (en) Novel dispersible lipid blends and uses therefor
AU3387597A (en) Twisting-cylinder display
AU5752398A (en) Novel ketobenzamides and their use
AU7442398A (en) Glucosamine fatty acid compositions and their use
AU6456598A (en) Universal introducer
AU6503299A (en) High-beta-conglycinin products and their use
AU8266898A (en) Display unit
AU2074797A (en) Flat-panel display
AU4564497A (en) Flat-panel display
AU9537098A (en) 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein
AU2921497A (en) View-changing display
AU6482398A (en) Sulfonylaminocarboxylic acids
AU9600598A (en) Visual display
AU6418498A (en) Human genes
AU9781998A (en) Huchordin and uses thereof
AU1890599A (en) Novel microorganism and use thereof
AU8739498A (en) Mannequin
AU4400496A (en) Display
AU6508898A (en) Improved display
AU5836498A (en) N-acyl-hydroxyamino acid esters and their use
AU6120298A (en) 2-peperazinone-1-acetic acid derivatives and their use
AU9357598A (en) Multipurpose display and support system
AU8074698A (en) (costal2) genes and their uses